Inhibrx Biosciences (INBX) Profit After Tax (2023 - 2026)

Inhibrx Biosciences (INBX) has reported Profit After Tax for 3 consecutive years, with -$32.8 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Profit After Tax rose 31.4% year-over-year to -$32.8 million; the TTM figure through Dec 2025 stood at -$140.1 million (down 108.3% YoY), while the FY2025 annual figure was -$140.1 million, down 108.3% from the prior year.
• Profit After Tax advanced to -$32.8 million in Q4 2025 per INBX's latest filing, from -$35.3 million in the prior quarter.
• Across five years, Profit After Tax topped out at $1.9 billion in Q2 2024 and bottomed at -$93.6 million in Q4 2023.
• Historically, Profit After Tax has averaged $123.2 million across 3 years, with a median of -$43.9 million in 2024.
• Annual changes were most pronounced in 2024 — Profit After Tax soared 4048.85% — and 2025, when it plunged 101.54%.
• Inhibrx Biosciences' Profit After Tax stood at -$93.6 million in 2023, then soared by 48.86% to -$47.9 million in 2024, then jumped by 31.4% to -$32.8 million in 2025.
• Business Quant data shows INBX's Profit After Tax at -$32.8 million in Q4 2025, -$35.3 million in Q3 2025, and -$28.7 million in Q2 2025.